Abstract 294P
Background
More than a third of small pelvis cancer cases in Uzbekistan are diagnosed in the late stages, where the main goal of medical interventions is to increase life expectancy with maximum maintenance of the quality of life. Opioid prescription and opiophobia in medical personnel make it harder to control pain in this group of patients, decreasing the quality of their life.
Methods
34 patients with locally advanced tumors of small pelvis (17 rectal cancer, 11 cervical cancer, 6 prostate cancer) with pain syndrome by visual analog scale (VAS) 8-10 were selected as the study group. Patients were treated in National cancer center of Uzbekistan in 2017-2020. Epidural catheter was placed in V4-5. Solution of bupivacaine 2.5% 20 ml with 1% of morphine injected at primary point. Then, 5 ml of bupivacaine 2.5% every 6 hours, 1 ml of 1% morphine every 12 hrs. Mean period of catheter placement was 23,6 days (7-36). in order to decrease the possibility of infection wide spectrum of antibiotics and wound dressing were administered. Control group included 34 patients with locally advanced tumors of small pelvis (20 rectal cancer, 12 cervical cancer, 2 prostate cancer) with pain syndrome by visual analog scale (VAS) 8-10. They underwent standard WHO pain ladder therapy morphine 1%-1 ml every 4-6 hrs ± ketorolac 30 mg – 1 ml.
Results
Withing the 20 minutes of administering, median pain syndrome by VAS was 0.78 (0-4). 6 (17.6%) patients admitted headache, 3 dizziness (8.8%). 2 patients admitted 1st grade nausea (5.9%). Constipation was not admitted in the main group. Drowsiness was admitted in 7 patients (20.6%). All of the symptoms disappeared within the 7 days period of hospitalization. In control group, the mean pain syndrome was 4.6 (0-7) by VAS. Drowsiness effect was observed in 27 patients (79.4), however, 21 (61.8%) cases this effect regressed in 7-day period. In 3-months observation period, 11 (32.6) patients from second group had complains on constipation which was resolved with laxatives and enemas.
Conclusions
Analgesia with usage of long-term epidural catheter placement allowed to achieve better pain control, lower opioid usage and avoid severe complications in patients with severe chronic pain syndrome of small pelvis tumors.
Clinical trial identification
N/A
Editorial acknowledgement
Legal entity responsible for the study
National Cancer Center of Uzbekistan.
Funding
National Cancer Center of Uzbekistan.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
403P - Clinical profile, practice pattern and outcomes in ALK-positive lung cancer: Real-world data from India
Presenter: Akhil Kapoor
Session: e-Poster Display Session
404P - Financial toxicity in patients with advanced lung cancer treated with immunotherapy: Has it an effect on the clinical decision?
Presenter: Jia-Hui Weng
Session: e-Poster Display Session
405P - Promising efficacy as combination therapy of DFP-14323, protease inhibitor, with EGFR-TKI in patients with metastatic NSCLC harboring EGFR mutation
Presenter: Hiroshige Yoshioka
Session: e-Poster Display Session
406P - Anti-PD-1 versus anti-PD-L1 inhibitors in first-line therapy non-small-cell lung cancer: A systematic review and meta-analysis
Presenter: Angelo Brito
Session: e-Poster Display Session
407P - Integrating histologic and genomic characteristics to predict tumour mutation burden of early-stage non-small cell lung cancer
Presenter: Yuan Qiu
Session: e-Poster Display Session
408P - Integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutation
Presenter: Julia Maevskaya
Session: e-Poster Display Session
409P - Effect of transdermal granisetron on prevention of nausea and vomiting during chemotherapy of lung cancer
Presenter: Haifeng Qin
Session: e-Poster Display Session
410P - Frequency and spectrum of primary resistance mechanism in Chinese ALK+ non-small cell lung cancer patients progressing on crizotinib: A multicenter study
Presenter: Wen-xian Wang
Session: e-Poster Display Session
411P - Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation
Presenter: Yoshihiko Taniguchi
Session: e-Poster Display Session
412P - Treatment patterns and selection criteria for advanced non-small cell lung cancer (NSCLC) patients unfit for platinum-based first-line therapy: Results of the MOON-OSS observational trial
Presenter: Andrea Camerini
Session: e-Poster Display Session